BMJ · 1972 · 315 citations · 23 references
Life SciencesImmunologyOncologyCancer ImmunologyCancer ScreeningTumor ImmunologyCancer BiomarkersImmuno-oncology BiomarkersMalignant NeoplasmsTumor AntigensTumor MarkersTumor-associated AntigensCancer AntigensCancer DiagnosticsEarly Cancer Detection MarkersImmune Biomarkers In CancerMalignant DiagnosisRoutine ScreeningSerum Tumor Markers
Our studies have confirmed that raised plasma levels of carcinoembryonic antigen (C.E.A.) occur with many but not all malignant tumours, particularly those of the gastrointestinal tract, breast, and bronchus. However, the incidence of raised values may reach 30% in diseases associated with inflammation or regeneration or both. Consequently, it cannot serve yet as a routine screening test for cancer. Effective surgical therapy results in high plasma C.E.A. levels returning to normal. Subsequent rises appear to develop with tumour recurrence or spread. At present the most useful role for C.E.A. seems to be in monitoring patients during the post-therapeutic followup period. Further basic work is required before C.E.A. can become of routine medical value.
23
Proceedings of the Royal Society of Medicine
Dermatology · 1912 · 914 citations · Full text
Proceedings of the American Association for Cancer Research.
Erik J M Konings, Piet A. van den Brandt, Wim H. M. Saris et al. · 2001 · 770 citations